Nonalcoholic fatty liver disease: an update
- PMID: 36853834
- DOI: 10.1097/MOL.0000000000000874
Nonalcoholic fatty liver disease: an update
Abstract
Purpose of review: We discuss two recent controversial issues in the research field of fatty liver: the proposal to replace nonalcoholic fatty liver disease (NAFLD) with metabolically associated fatty liver disease (MAFLD) and the suggestion to extend to primary care the noninvasive testing for liver fibrosis that was developed for secondary care.
Recent findings: There is preliminary evidence that MAFLD-only patients are at greater risk of fibrosis than NAFLD-only patients. There are a large number of false positives associated with the downshift of noninvasive testing for liver fibrosis from secondary to primary care.
Summary: More studies are needed to compare the MAFLD and NAFLD operational definitions. Noninvasive testing of liver fibrosis also needs further evaluation before it can be used in primary care or in the general population.
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Similar articles
-
Fibrosis-4 Index Score Predicts Concomitant Coronary Artery Diseases Across the Spectrum of Fatty Liver Disease.Dig Dis Sci. 2023 Sep;68(9):3765-3773. doi: 10.1007/s10620-023-07987-1. Epub 2023 Jul 1. Dig Dis Sci. 2023. PMID: 37392337
-
Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name.Clin Mol Hepatol. 2022 Oct;28(4):790-801. doi: 10.3350/cmh.2022.0070. Epub 2022 May 11. Clin Mol Hepatol. 2022. PMID: 35545437 Free PMC article. Review.
-
The search for noninvasive methods to identify liver fibrosis in children with nonalcoholic fatty liver disease.Biomark Med. 2018 Mar;12(3):265-273. doi: 10.2217/bmm-2017-0038. Epub 2018 Mar 8. Biomark Med. 2018. PMID: 29517271 Review.
-
Clinicopathological Profile and Outcome of a Large Cohort of Patients with Nonalcoholic Fatty Liver Disease from South Asia: Interim Results of the Indian Consortium on Nonalcoholic Fatty Liver Disease.Metab Syndr Relat Disord. 2022 Apr;20(3):166-173. doi: 10.1089/met.2021.0104. Epub 2022 Jan 25. Metab Syndr Relat Disord. 2022. PMID: 35085026
-
Noninvasive fibrosis tools in NAFLD: validation of APRI, BARD, FIB-4, NAFLD fibrosis score, and Hepamet fibrosis score in a Portuguese population.Postgrad Med. 2022 May;134(4):435-440. doi: 10.1080/00325481.2022.2058285. Epub 2022 Mar 30. Postgrad Med. 2022. PMID: 35332833
Cited by
-
The effects of cGAS-STING inhibition in liver disease, kidney disease, and cellular senescence.Front Immunol. 2024 Jul 24;15:1346446. doi: 10.3389/fimmu.2024.1346446. eCollection 2024. Front Immunol. 2024. PMID: 39114669 Free PMC article. Review.
References
-
- Eslam M, Sanyal AJ, George J. International Consensus Panel. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 2020; 158:1999.e1–2014.e1.
-
- Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol 2020; 73:202–209.
-
- Singh SP, Anirvan P, Reddy KR, et al. Nonalcoholic fatty liver disease: not time for an obituary just yet. J Hepatol 2021; 74:972–974.
-
- Younossi ZM, Rinella ME, Sanyal AJ, et al. From NAFLD to MAFLD: implications of a premature change in terminology. Hepatology 2021; 73:1194–1198.
-
- Singh SP, Anirvan P, Khandelwal R, Satapathy SK. Nonalcoholic fatty liver disease (NAFLD) name change: Requiem or Reveille. J Clin Translat Hepatol 2021; 9:931–938.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials